Validated using a knockout cell line
Recombinant
RabMAb

Recombinant Anti-NFkB p105 / p50 antibody [E381] - BSA and Azide free (ab220803)

Overview

  • Product name

    Anti-NFkB p105 / p50 antibody [E381] - BSA and Azide free
    See all NFkB p105 / p50 primary antibodies
  • Description

    Rabbit monoclonal [E381] to NFkB p105 / p50 - BSA and Azide free
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IHC-Pmore details
    Unsuitable for: Flow Cyt
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to NFkB p105/ p50 aa 300-400.

  • Positive control

    • WB: HeLa, MCF-7 and PC-12 cell lysates. IHC-P: human prostate carcinoma and bladder carcinoma tissues.
  • General notes

    Ab220803 is the carrier-free version of ab32360. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    ab220803 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab220803 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Detects a band of approximately 50, 105 kDa (predicted molecular weight: 50 kDa).
IHC-P Use at an assay dependent concentration.

See IHC antigen retrieval protocols.

  • Application notes
    Is unsuitable for Flow Cyt.
  • Target

    • Function

      NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3', located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.
    • Sequence similarities

      Contains 7 ANK repeats.
      Contains 1 death domain.
      Contains 1 RHD (Rel-like) domain.
    • Domain

      The C-terminus of p105 might be involved in cytoplasmic retention, inhibition of DNA-binding, and transcription activation.
      Glycine-rich region (GRR) appears to be a critical element in the generation of p50.
    • Post-translational
      modifications

      While translation occurs, the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like), being able to form cytosolic complexes with NF-kappa B, trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.
      Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.
      Polyubiquitination seems to allow p105 processing.
      S-nitrosylation of Cys-61 affects DNA binding.
    • Cellular localization

      Nucleus. Cytoplasm. Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor.
    • Information by UniProt
    • Database links

    • Alternative names

      • DKFZp686C01211 antibody
      • DNA binding factor KBF1 antibody
      • DNA binding factor KBF1 EBP1 antibody
      • DNA-binding factor KBF1 antibody
      • EBP 1 antibody
      • EBP-1 antibody
      • EBP1 antibody
      • KBF1 antibody
      • MGC54151 antibody
      • nf b antibody
      • NF kappa B antibody
      • NF kappaB antibody
      • NF kappabeta antibody
      • NF kB1 antibody
      • NF-kappaB antibody
      • NFkappaB antibody
      • NFKB 1 antibody
      • NFKB p105 antibody
      • NFKB p50 antibody
      • NFKB-p105 antibody
      • Nfkb1 antibody
      • NFKB1_HUMAN antibody
      • Nuclear factor kappa B DNA binding subunit antibody
      • Nuclear factor kappa-B antibody
      • Nuclear factor kappa-B, subunit 1 antibody
      • Nuclear factor NF kappa B p105 subunit antibody
      • Nuclear factor NF kappa B p50 subunit antibody
      • Nuclear factor NF-kappa-B p50 subunit antibody
      • Nuclear factor of kappa light chain gene enhancer in B cells 1 antibody
      • Nuclear factor of kappa light polypeptide gene enhancer in B cells 1 antibody
      • Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 antibody
      • p105 antibody
      • p50 antibody
      • p84/NF-kappa-B1 p98 antibody
      • Transcription factor NFKB1 antibody
      see all

    Images

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human bladder carcinoma tissue labelling NFkB p105 / p50 with purified ab32360 at 1/250. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. ab97051, a HRP-conjugated goat anti-rabbit IgG (H+L) was used as the secondary antibody (1/500). Negative control using PBS instead of primary antibody. Counterstained with hematoxylin.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32360).

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human prostate carcinoma tissue labelling NFkB p105 / p50 with unpurified ab32360 at a dilution of 1/250.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab32360).

    References

    This product has been referenced in:

    • Gong H  et al. Tumor necrosis factor-related apoptosis-inducing ligand inhibits the growth and aggressiveness of colon carcinoma via the exogenous apoptosis signaling pathway. Exp Ther Med 17:41-50 (2019). Read more (PubMed: 30651763) »
    • Wang Z  et al. Lipopolysaccharide Preconditioning Increased the Level of Regulatory B cells in the Spleen after Acute Ischaemia/Reperfusion in Mice. Brain Res N/A:N/A (2018). Read more (PubMed: 29803621) »
    See all 25 Publications for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab220803.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up